Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: One-year data

British Journal of Cardiology

Volumn 8, Issue 1, 2001, Pages 36-37

  Bosanquet, N ^a   Fox, K A A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035154162     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease
2. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events study group
3. Randomised trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One year results of the ESSENCE study
4. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) IIB trial
5. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: Results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]